Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
US9132120B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 4, 2013 |
| Grant date | Sep 15, 2015 |
| Priority date | — |
| Expiry date | Jul 27, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A90/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.